Proteins and Peptides
19 December 2016
ProMetic initiates rolling submission of its Biologics License Application (“BLA”) for plasminogen with U.S. FDA17 December 2016
Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with type 1 diabetes13 December 2016
Ferring Receives EU Approval for REKOVELLE® (follitropin delta)13 December 2016
Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics13 December 2016
Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial12 December 2016
Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)8 December 2016
Horizon Pharma plc Announces Topline Results from Phase 3 Study of ACTIMMUNE® (interferon gamma-1b) in Friedreich’s Ataxia8 December 2016
Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease8 December 2016
Avelas Presents Phase 1b Clinical Trial Data for AVB-620 at 2016 San Antonio Breast Cancer Symposium7 December 2016
MolMed files a Conditional Marketing Authorisation in the European Union for NGR-hTNF5 December 2016
Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes5 December 2016
Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis5 December 2016
BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 20161 December 2016
Bicycle Therapeutics Announces Broad Partnership with Astrazeneca to Develop Bicyclic Peptides (Bicycles®)29 November 2016
Oramed’s ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study29 November 2016
Coherus’ Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted25 November 2016
GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney disease22 November 2016
Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes22 November 2016
Novo Nordisk receives US FDA approval for Xultophy® 100/3.622 November 2016
Sanofi Receives FDA Approval of Soliqua(TM) 100/33 for the Treatment of Adults with Type 2 DiabetesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports